All In Biotech

Drug Trial Radar · NCT05417321

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Aug 25, 2022

Primary completion

Aug 1, 2025

Study completion Aug 1, 2025

Sponsor

Sponsor type
Industry
First posted
Jun 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors

Conditions

  • Advanced Solid Tumor
  • NSCLC

Interventions

  • HB0036Drug

    Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerabilityTime frame: Up to 12 Months
  2. MTDTime frame: Up to 24 Months

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Horizon Oncology

    Lafayette, Indiana · Recruiting

  • Next Oncology

    San Antonio, Texas · Recruiting

  • Summit Cancer Centers

    Spokane, Washington · Recruiting

  • Shandong Hospital

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.